Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03971669 · ClinicalTrials.gov registry record · Phase 4
Blood Donor CVD 5000
A Phase 4 study of Risk Reduction, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03971669 is a Phase 4 study of Risk Reduction that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 150 participants, below the 3,687-participant average among 13 other Risk Reduction trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03971669, a Phase 4 study of Risk Reduction, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood, saliva, and stool specimens over a follow-up time period of up to eight years. The specimens obtained in this clinical research study will be used to further the investigator's understanding of the protective immunological mechanisms that can be elicited systemically and may be applicable to other enteric pathogens.
Conditions Studied
Interventions
- DRUG Vivotif Typhoid Oral Vaccine
Study Locations (1)
Maryland
- University of Maryland, Baltimore, Center for Vaccine Development and Global Health - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-01-16 |
| Est. Completion | 2030-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03971669
The ClinicalTrials.gov registry entry for NCT03971669 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,687-participant average among 13 other Risk Reduction trials with a reported enrollment target (96% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Risk Reduction appearing as the primary indexed condition, and to 1 intervention - of which Vivotif Typhoid Oral Vaccine is the first listed.
NCT03971669 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03971669 about?
NCT03971669 is a clinical study titled "Blood Donor CVD 5000". This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood, saliva, and stool specimens ov...
What is the current status of trial NCT03971669?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2004-01-16. Estimated completion is 2030-06-30.
What conditions does trial NCT03971669 study?
This clinical trial studies the following conditions: Risk Reduction.
What interventions are being tested in trial NCT03971669?
The interventions under investigation include: Vivotif Typhoid Oral Vaccine (DRUG).
Who is sponsoring clinical trial NCT03971669?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03971669 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Risk Reduction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
RECRUITING
-
Tennessee Youth Prepared for Success
ACTIVE NOT RECRUITING · NA
-
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
ACTIVE NOT RECRUITING · Phase 2
-
PrEP Point-of-Care Brief-Intervention for Adherence Among Young Men Who Have Sex With Men
COMPLETED · NA
-
Efficacy of Communication Modalities for Promoting Flu Shots
COMPLETED · NA
-
Nature and Health: How Does Lifestyle and Environment Affect Health and Wellness
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.